Tresiba Penfill 100 IU Inj 3 ml Cartridge

• Treatment of Diabetes

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Tresiba Penfill 100 IU Inj 3 ml   also causes some adverse impact on the body, most of which resolve without any medical attention.

Some common side effects include:

• Auto-antibody formation
• Headache
• Injection site reactions (pain, swelling, redness)
• Severe hypoglycemia
• Nasopharyngitis (inflammation of the throat and nasal passages)
• Upper respiratory tract infection

Seek medical attention in case of any unusual or severe side effects immediately.

• Dosage of the Tresiba Penfill 100 IU Inj 3 ml decide according to the type of diabetes and overall health condition of the patient. This injection can be administered by a doctor or nurse or your care giver may be taught on how to use this medicine at home.
• In case of an overdose, the doctor will provide emergency medical treatment. Do not stop or change the dose without informing your doctor.​
  

• Tresiba Penfill 100 IU Inj 3 ml is a prescription based long-acting type of insulin. it helps to treat type 1 & type 2 diabetes by providing consistent and all-day sugar control. It works like the body's natural insulin.
• Insulin facilitates the reuptake of sugar in muscle and fat cells as well as suppresses sugar production in the liver.​
  

• Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., ... & Bode, B. (2012). Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet, 379(9825), 1489-1497. https://pubmed.ncbi.nlm.nih.gov/22521071/
• Garber, A. J., King, A. B., Del Prato, S., Sreenan, S., Balci, M. K., Muñoz-Torres, M., ... & Hollander, P. (2012). Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet, 379(9825), 1498-1507. https://pubmed.ncbi.nlm.nih.gov/22521072/
• Heise, T., Hoevelmann, U., Nosek, L., Hermanski, L., Bøttcher, S. G., & Haahr, H. (2015). Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert opinion on drug metabolism & toxicology, 11(8), 1193-1201. https://pubmed.ncbi.nlm.nih.gov/26086190/
• Vora, J., Cariou, B., Evans, M., Gross, J. L., Harris, S., Landstedt-Hallin, L., ... & Meneghini, L. (2015). Clinical use of insulin degludec. Diabetes research and clinical practice, 109(1), 19-31.
• Haahr, H., & Heise, T. (2014). A review of the pharmacological properties of insulin degludec and their clinical relevance. Clinical pharmacokinetics, 53(9), 787-800.